Signal active
Bio
Sanjay Mistry is the director at Rapport Therapeutics. Joined Quaker Partners in 2008. Dr. Mistry focused on selecting investments across the biopharma and diagnostics/tools sectors.
Prior to joining Quaker, he was an Assistant Director at Johnson & Johnson, where he held responsibilities in therapeutic area strategy planning and in the implementation and management of life science alliances for the Stem Cell Internal Ventures (SCIV) group.
Prior to his business development roles, he led stem cell translational development in the area of retinal degeneration within the SCIV. Dr. Mistry also worked at Morphogen Pharmaceuticals and completed postdoctoral fellowships at the Scripps Research Institute and at the University of Pittsburgh Medical School.
He holds a Ph.D. in Biochemical Pharmacology and an M.S. in Clinical Pharmacology from the University of Aberdeen and a B.Sc. in Applied Biology from Nottingham.
Location
San Diego, California, United States, North America
Social
Primary Organization
2022
11-50
Biotechnology, Life Science, Health Care, Medical, Precision Medicine
Jobs history
2
Rapport Therapeutics
Director
2022 - Current
Rapport Therapeutics
Board Member
Invalid date - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Sanjay Mistry is the Director at Rapport Therapeutics, based in United States, North America. With a background in Biotechnology, Sanjay Mistry has a rich history of leadership and innovation. Sanjay Mistry studied BS Applied Biology @ University of Nottingham. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
2
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Mar 07, 2023 | Rapport Therapeutics | Series A - Rapport Therapeutics | - | 100.0M |
Aug 23, 2023 | Rapport Therapeutics | Series B - Rapport Therapeutics | - | 150.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.